All Outputs (2)

Near-infrared PbS quantum dots functionalized with affibodies and ZnPP for targeted imaging and therapeutic applications (2021)
Journal Article
Al-Ani, A. W., Zamberlan, F., Ferreira, L., Bradshaw, T. D., Thomas, N. R., & Turyanska, L. (2021). Near-infrared PbS quantum dots functionalized with affibodies and ZnPP for targeted imaging and therapeutic applications. Nano Express, 2(4), Article 040005. https://doi.org/10.1088/2632-959x/ac33b8

We report a new theranostic device based on lead sulfide quantum dots (PbS QDs) with optical emission in the near infrared wavelength range decorated with affibodies (small 6.5 kDa protein-based antibody replacements) specific to the cancer biomarker... Read More about Near-infrared PbS quantum dots functionalized with affibodies and ZnPP for targeted imaging and therapeutic applications.

New InhA Inhibitors Based on Expanded Triclosan and Di-Triclosan Analogues to Develop a New Treatment for Tuberculosis (2021)
Journal Article
Chetty, S., Armstrong, T., Sharma Kharkwal, S., Drewe, W. C., De Matteis, C. I., Evangelopoulos, D., …Thomas, N. R. (2021). New InhA Inhibitors Based on Expanded Triclosan and Di-Triclosan Analogues to Develop a New Treatment for Tuberculosis. Pharmaceuticals, 14(4), Article 361. https://doi.org/10.3390/ph14040361

The emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) has reinforced the need for the development of new anti-TB drugs. The first line drug isoniazid inhibits InhA. This is a prodrug requiring activation by... Read More about New InhA Inhibitors Based on Expanded Triclosan and Di-Triclosan Analogues to Develop a New Treatment for Tuberculosis.